<DOC>
	<DOCNO>NCT01585233</DOCNO>
	<brief_summary>The purpose study explore safety tolerability multiple dos ASKP1240 compare placebo determine Pharmacokinetics Pharmacodynamics subject moderate severe psoriasis .</brief_summary>
	<brief_title>A Multiple Dose Escalation Study ASKP1240 Subjects With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>Treatment ASKP1240 placebo 4 week ( Baseline/Day 1 , Days 15 Day 29 ) 12 week follow-up total 16 week .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject clinical diagnosis moderate severe plaque psoriasis 6 month longer least 5 % great Body Surface Area ( BSA ) affect plaque psoriasis Subject must candidate phototherapy and/or systemic therapy Subject must agree avoid prolonged exposure sun avoid use tan booths ultraviolet light source study Female subject must either : postmenopausal ( define least 1 year without menses ) prior Screening , premenarchal prior Screening , document surgically sterile status post hysterectomy ( least 1 month prior Screening ) , childbearing potential , must negative serum pregnancy test Screening sexually active must use highly effective contraception . All sexually active subject require use highly effective contraception consist two form birth control ( one must barrier method ) start Screening throughout study period 28 day [ 5 five half life study drug whichever longer ] final study drug administration . Female subject must lactate must breastfeed Screening study period 28 day [ 5 five half life study drug whichever longer ] final study drug administration . Female subject must donate ovum start Screening throughout study period 28 day [ 5 five half life study drug whichever longer ] final study drug administration . Male subject female spouse/partners sexually active must use highly effective contraception1 consist two form birth control ( one must barrier method ) start Screening continue throughout study period 28 day [ 5 five half life study drug whichever longer ] final study drug administration . Male subject must donate sperm start Screening throughout study period least 28 day [ 5 five half life study drug whichever longer ] final study drug administration . Highly effective contraception define : Established use oral , injected implant hormonal method contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Barrier method contraception : Condom alone Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . Subject must willing able comply study requirement , include prohibit concomitant medication restriction . Waivers inclusion criterion NOT allow . Subject nonplaque psoriasis ( guttate , erythrodermic pustular psoriasis ) Subject receive treatment systemic , nonbiologic psoriasis therapy systemic immunosuppressant include investigational use approve agent within last 30 day 5 halflives , whichever longer , prior first dose study drug Subject ever treat efalizumab ( Raptiva® ) Subject total B lymphocyte count flow cytometric determination less low limit normal Subject hemoglobin , low limit Subject total white count , total lymphocyte count , total neutrophil count total platelet lower limit Subject follow lab value : ALT ≥ 1.5 x upper limit normal AST ≥ 1.5 x upper limit normal Total bilirubin ≥ 1.5 x upper limit normal Subject previously receive ASKP1240 participate study involve ASKP1240 Subject &gt; 45 body mass index ( BMI ) Subject positive Tubercle Bacillus ( TB ) test previously receive adequate antimicrobial therapy TB currently , plan start TB antimicrobial therapy Subject abnormal chest xray indicative acute chronic lung disease Subject uncontrolled intercurrent illness , include , limited ongoing active infection , clinically significant cardiac disease seizure disorder , psychiatric illness/social situation would limit compliance study requirement Subject history malignancy regardless location time diagnosis last 5 year ( include insitu carcinoma cervix , exclude successfully treat nonmetastatic basal cell squamous cell carcinoma ) Subject receive live live attenuate virus vaccination within last 30 day prior first dose study drug Subject receive treatment another investigational drug within 30 day 5 halflives ; whichever longer , prior initiation Screening Subject positive test hepatitis B surface antigen ( HBsAg ) hepatitis C ( HCV ) antibody Subject history positive test human immunodeficiency virus ( HIV ) infection Subject receive treatment systemic , biologic psoriasis therapy systemic immunosuppressant include investigational use approve agent within last 56 day 5 halflives whichever longer , prior first dose study drug Waivers exclusion criterion NOT allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Moderate Psoriasis</keyword>
	<keyword>Severe Psoriasis</keyword>
	<keyword>Skin disease</keyword>
	<keyword>ASKP1240</keyword>
	<keyword>CD40 antigen</keyword>
	<keyword>Anti-CD40 monoclonal antibody</keyword>
</DOC>